Table 2.
Characteristics of the study sample with prediabetes, divided by sex.
| n (female/male) | Female | Male | p value | |
|---|---|---|---|---|
| Age [years]∗ | 19/29 | 62.4 ± 9.6 | 54.4 ± 9.8 | 0.007 |
| Body weight | 19/28 | 73.50 ± 13.62 | 90.49 ± 13.55 | <0.001 |
| BMI [kg/m2]∗ | 19/28 | 27.8 ± 4.8 | 28.9 ± 3.7 | 0.360 |
| Waist [cm]∗ | 18/27 | 94.9 ± 9.2 | 104.4 ± 8.9 | 0.001 |
| RRS [mmHg]∗ | 14/20 | 127.5 ± 17.6 | 136.4 ± 18.2 | 0.164 |
| RRD [mmHg]∗ | 14/20 | 77.2 ± 10.7 | 82.1 ± 11.5 | 0.223 |
| TC [mg/dL]∗ | 19/29 | 238.6 ± 68.3 | 231.6 ± 81.5 | 0.371 |
| LDL-C [mg/dL]∗ | 18/27 | 136.2 ± 50.2 | 131.5 ± 45.4 | 0.746 |
| HDL-C [mg/dL]∗ | 17/27 | 62.7 ± 16.1 | 43.7 ± 14.6 | <0.001 |
| NHDL-C [mg/dL]∗ | 17/27 | 164.3 ± 47.4 | 171.5 ± 50.5 | 0.640 |
| ln(TG) [mg/dL]∗ | 19/29 | 5.2 ± 0.69 | 5.55 ± 0.76 | 0.165 |
| ln(TG/HDL)∗ | 17/27 | 0.97 ± 0.66 | 1.70 ± 0.81 | 0.003 |
| ln(Lip.a) [units]∗ | 17/26 | 4.00 ± 1.04 | 2.96 ± 1.40 | 0.013 |
| IMT-left [mm]∗ | 17/26 | 0.68 ± 0.18 | 0.69 ± 0.17 | 0.576 |
| IMT-right [mm]∗ | 17/26 | 0.69 ± 0.16 | 0.66 ± 0.14 | 0.463 |
| IMT av [mm]∗ | 17/26 | 0.69 ± 0.15 | 0.68 ± 0.14 | 0.834 |
| Glucose [mg/dL]∗ | 19/27 | 99.8 ± 9.2 | 100.3 ± 12.0 | 0.882 |
| ln(insulin+1) [μU/mL]∗ | 17/27 | 2.15 ± 0.77 | 2.41 ± 0.75 | 0.273 |
| C-peptide [ng/mL]∗ | 16/23 | 3.44 ± 2.55 | 3.03 ± 1.16 | 0.656 |
| HbA1c [%]∗ | 19/28 | 5.83 ± 0.32 | 5.73 ± 0.33 | 0.322 |
| QUICKI-test∗ | 16/23 | 0.36 ± 0.05 | 0.35 ± 0.05 | 0.478 |
| ln(proBNP) [units]∗ | 16/23 | 4.18 ± 0.61 | 4.23 ± 1.51 | 0.905 |
| ln(hsCRP+1) [units]∗ | 17/28 | 0.30 ± 0.29 | 0.20 ± 0.17 | 0.440 |
| ln(GOT) [mg/dL]∗ | 18/29 | 3.34 ± 0.35 | 3.41 ± 0.37 | 0.499 |
| ln(GPT) [mg/dL]∗ | 18/29 | 3.32 ± 0.45 | 3.55 ± 0.46 | 0.098 |
| ln(GGT) [mg/dL]∗ | 18/29 | 3.52 ± 0.78 | 3.96 ± 0.70 | 0.048 |
| Ezetimibe∗∗ | 19/23 | 2 (10.5) | 3 (13.0) | 1.000 |
| Nicotinic acid∗∗ | 19/23 | 0 (0.0) | 2 (8.7) | 0.556 |
| Fibrates∗∗ | 19/23 | 2 (10.5) | 9 (39.1) | 0.081 |
| Statins∗∗ | 19/23 | 11 (57.9) | 19 (82.6) | 0.155 |
| CVD∗∗ | 18/27 | 1 (5.6) | 8 (29.6) | 0.110 |
| Mean steps 7 days∗ | 17/21 | 7009.8 ± 2520.4 | 8381.4 ± 2660.0 | 0.114 |
| Metabolic syndrome∗∗ | 12/20 | 5 (41.7) | 12 (60.0) | 0.522 |
| Mean treatment duration of the last taken dyslipidemic medication (days)∗ | 18/28 | 2272.3 ± 2649.9 | 2132.8 ± 2362.1 | 0.938 |
∗ t-test, ∗∗Chi-square test.
Data are presented as number of observations (n) and means ± standard deviation. BMI (body mass index), waist (waist circumference), RRS (systolic blood pressure), RRD (diastolic blood pressure), TC (total cholesterol), LDL-C (low density lipoprotein cholesterol), HDL-C (high density lipoprotein cholesterol), NHDL-C (non-high density lipoprotein cholesterol), TG (triglycerides), TG/HDL (triglyceride/HDL-cholesterol ratio), Lip.a (lipoprotein (a)), IMT (carotid intima media thickness), HbA1c (glycated hemoglobin A1c), QUICKI (quantitative insulin sensitivity check index), proBNP (pro B-type natriuretic peptide), hsCRP (high sensitive C-reactive protein), GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transaminase), GGT (gamma-glutamyl transferase), and CVD (cardiovascular disease).